HER2 LOW BREAST CARCINOMA
Clinical trials for HER2 LOW BREAST CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HER2 LOW BREAST CARCINOMA trials appear
Sign up with your email to follow new studies for HER2 LOW BREAST CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New Antibody-Drug combo shows promise for Hard-to-Treat breast cancer
Disease control Recruiting nowThis phase II trial is testing a drug called ARX788 in 36 people with HER2-low breast cancer that has spread or cannot be removed. ARX788 is an antibody-drug conjugate that delivers a toxin directly to cancer cells with the HER2 protein. The main goal is to see how many patients'…
Matched conditions: HER2 LOW BREAST CARCINOMA
Phase: PHASE2 • Sponsor: Laura Huppert, MD, BA • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
New drug duo aims to outsmart resistant breast cancer
Disease control Recruiting nowThis study tests a combination of two drugs—elacestrant and trastuzumab deruxtecan—in people with a specific type of advanced breast cancer (HR-positive, HER2-low or ultralow) that has stopped responding to standard hormone therapy and CDK4/6 inhibitors. The goal is to find the s…
Matched conditions: HER2 LOW BREAST CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Kristina A. Fanucci • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC